News and Media
Registration now open for the Mark Ernsting Drug Discovery Memorial Lecture
Join us for the inaugural Mark Ernsting Drug Discovery Memorial Lecture. The Lecture is named in honour of Dr. Mark Ernsting, who was a Senior Biomedical Engineer in the Drug Discovery Program at OICR. Dr. Ernsting passed away in December 2015. He was a brilliant and passionate scientist and a great colleague and friend. Dr. Ernsting endeavoured to improve the lives of cancer patients by developing nanomedicines designed to deliver safer and more effective drugs.

Mark Ernsting Lecture

Join us for the inaugural Mark Ernsting Drug Discovery Memorial Lecture. The Lecture is named in honour of Dr. Mark Ernsting, who was a Senior Biomedical Engineer in the Drug Discovery Program at OICR. Dr. Ernsting passed away in December 2015. He was a brilliant and passionate scientist and a great colleague and friend. Dr. Ernsting endeavoured to improve the lives of cancer patients by developing nanomedicines designed to deliver safer and more effective drugs.

Title of talk: Chemistry towards novel mechanism-of-action (nMoA) compounds in therapeutics discovery

Speaker: Stuart L. Schreiber, PhD
Morris Loeb Professor
Director, Center for the Science of Therapeutics
Harvard University
Broad Institute of MIT and Harvard

When: September 22, 2016, 3-5 p.m.

Where: The Great Hall, Hart House, University of Toronto, 7 Hart House Circle, Toronto, Ontario M5S 3H3

More information and free registration:
https://www.eventbrite.ca/e/mark-ernsting-drug-discovery-memorial-lecture-given-by-dr-stuart-schreiber-tickets-27005851228